Cramer Remix: I think this is a great spec play that could get acquired

Jim Cramer explains that bluebird bio's technology offerings make it attractive for a potential takeover.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.